Gut Microbiota Associated with Clinical Relapse in Patients with Quiescent Ulcerative ColitisOriginal paper
Karen Pendergrass is a microbiome researcher specializing in microbiome-targeted interventions (MBTIs). She systematically analyzes scientific literature to identify microbial patterns, develop hypotheses, and validate interventions. As the founder of the Microbiome Signatures Database, she bridges microbiome research with clinical practice. In 2012, based on her own investigative research, she became the first documented case of FMT for Celiac Disease, four years before the first published case study.
Read MoreWhat was studied?
Researchers compared fecal microbiota in 59 Japanese patients with quiescent ulcerative colitis and 59 healthy controls, then followed the patients for up to 3.5 years to see which gut bacteria predicted relapse.
How was it studied?
Fecal samples underwent 16S rRNA gene amplicon sequencing. Functional shifts in the microbiota were predicted with PICRUSt against the KEGG database, and patients were grouped into clusters analyzed with Kaplan-Meier survival curves and LEfSe.
What did they find?
Thirteen taxa distinguished healthy controls from quiescent ulcerative colitis patients. Between-sample community composition (beta diversity) differed by relapse status even though within-sample diversity (alpha diversity) did not. Prevotella was more abundant in patients who stayed in remission, while Faecalibacterium and Bifidobacterium were more abundant in those who relapsed. Four microbiota-based clusters showed distinct clinical courses and 48 differentially active metabolic pathways.
Why it matters
Identifying Prevotella, Faecalibacterium, and Bifidobacterium as relapse-associated genera suggests fecal microbiota profiling could help stratify quiescent ulcerative colitis patients by relapse risk.